Mycoplasma Testing Market Report 2026

The mycoplasma testing market size has grown rapidly in recent years. It will grow from $1.23 billion in 2025 to $1.38 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to high prevalence of mycoplasma contamination, increased reliance on cell culture testing, growth in diagnostic testing demand, early adoption of pcr methods, rising use of elisa techniques.

The mycoplasma testing market size is expected to see rapid growth in the next few years. It will grow to $2.1 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to expansion of biopharmaceutical manufacturing, growth in cro outsourcing, increased investment in genomic testing, rising regulatory emphasis on contamination control, adoption of automated testing platforms. Major trends in the forecast period include growing adoption of pcr-based mycoplasma detection, increasing use of rapid test kits for cell culture screening, rising demand for automated mycoplasma detection systems, expansion of assay and reagent usage in biopharmaceutical production, higher need for mycoplasma testing in research and cro settings.

The growing prevalence of mycoplasma pneumonia is expected to propel the growth of the mycoplasma testing market going forward. Mycoplasma pneumonia is a respiratory infection caused by the bacterium Mycoplasma pneumoniae. Mycoplasma testing plays a vital role in diagnosing this condition by identifying the presence of Mycoplasma pneumoniae in respiratory samples, supporting timely and accurate diagnosis for appropriate treatment and disease management. For instance, in December 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, an estimated 2 million cases of Mycoplasma pneumoniae infections occur annually in the United States. Therefore, the increasing prevalence of mycoplasma pneumonia is driving the growth of the mycoplasma testing market.

Major companies operating in the mycoplasma testing market are increasingly focusing on launching digital PCR kits to gain a competitive advantage. Digital PCR kits are molecular diagnostic tools that allow highly accurate quantification and analysis of nucleic acids, such as DNA or RNA, using a digital-based detection approach. For instance, in November 2023, QIAGEN, a Germany-based diagnostics company, introduced three new QIAcuity digital PCR kits along with updated software to broaden the application of digital PCR in biopharmaceutical research and food safety testing. These QIAcuity kits are designed to deliver precise quantification and are offered in one-, four-, and eight-plate formats, with the single-plate version capable of processing up to 384 samples within an eight-hour shift. Among the newly launched products, the QIAcuity Mycoplasma Quant Kit provides researchers with a highly accurate and reliable method for detecting mycoplasma contamination across all stages of research workflows.

In May 2024, bioMérieux S.A., a France-based biotechnology company, announced a partnership with AnaBioTec to strengthen mycoplasma testing approaches in the biopharmaceutical sector. Through this collaboration, bioMérieux aims to advance mycoplasma testing methodologies by addressing the limitations of conventional techniques, which often involve long processing times of up to 28 days and are not well suited to the rapid pace of biopharma operations. AnaBioTec is a Belgium-based analytical services provider specializing in mycoplasma testing.

Major companies operating in the mycoplasma testing market are Merck KGaA, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Lonza Group AG, Roche Diagnostics International AG, Charles River Laboratories International Inc., Nelson Laboratories Fairfield Inc., Creative Bioarray, Biological Industries Israel Beit Haemek Ltd., Biotools B & M Labs S.A, PromoCell GmbH, American Type Culture Collection, Bionique Testing Laboratories Inc., InvivoGen, Clongen Laboratories LLC, Norgen Biotek Corporation, Gen Bio Sciences (P) Ltd., GeneCopoeia Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Savyon Diagnostics, ScienCell Research Laboratories Inc.

North America was the largest region in the mycoplasma testing market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the mycoplasma testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mycoplasma testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariff regulations on laboratory instruments, assay components, and imported diagnostic equipment have contributed to higher manufacturing and procurement costs in the mycoplasma testing market. The most impacted segments include PCR systems, detection kits, and specialized reagents, particularly in regions that rely heavily on international suppliers such as Asia-Pacific and Latin America. However, these tariffs have encouraged localized production and stimulated investment in domestic biotechnology manufacturing, which may reduce long-term dependency on imported testing tools.

The mycoplasma testing market research report is one of a series of new reports that provides mycoplasma testing market statistics, including mycoplasma testing industry global market size, regional shares, competitors with a mycoplasma testing market share, detailed mycoplasma testing market segments, market trends and opportunities, and any further data you may need to thrive in the mycoplasma testing industry. This mycoplasma testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mycoplasma testing is used to detect *Mycoplasma pneumoniae*, the causative agent of mycoplasma pneumonia. Mycoplasma pneumonia is a contagious respiratory infection that spreads easily through contact with respiratory secretions and can lead to outbreaks. Mycoplasma testing comprises a group of tests that measure antibodies produced in response to infection and directly detect the microorganism by identifying or culturing its genetic material (DNA) from body samples.

The main types of mycoplasma testing technologies include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic methods, and deoxyribonucleic acid (DNA) staining. PCR detects mycoplasma species using primers specific to mycoplasma DNA, typically targeting the 16S rRNA genes. ELISA identifies mycoplasma through antibodies or labeled probes directed at the mycoplasma 16S rRNA genes. Enzymatic methods analyze suspected cell culture samples that convert ADP to ATP using mycoplasmal enzymes. DNA staining identifies *M. hyorhinis* by culturing suspected samples with Vero cells and staining cellular DNA with fluorescent dyes. The products used in mycoplasma testing include instruments, assays, kits, and reagents. Mycoplasma testing is applied in cell line testing, virus testing, and end-of-production cell testing and is utilized by pharmaceutical and biotechnology companies, cell banks and laboratories, contract research organizations, and academic research institutes.

The mycoplasma testing market includes revenues earned by entities by PCR detection assay, indirect hoechst stain, and culture isolation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.